EXPECTED OUTCOMES The study will provide information on the impact of tobacco use on health from epidemiological, social and economic perspectives in relation.

Slides:



Advertisements
Similar presentations
2/9/2014 The Prevalence and Prognostic Significance of ECG Abnormalities For: ECG in Ischemic Heart Disease By: V. Froelicher, MD Palo Alto VAHCS and Stanford.
Advertisements

Summary Prepared by Melvyn Rubenfire, MD
1 Epidemiologic Measures of Association Saeed Akhtar, PhD Associate Professor, Epidemiology Division of Epidemiology and Biostatistics Aga Khan University,
Session 2: Assessing cost- effectiveness of individual level interventions ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research.
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
An introduction Epidemiology matters: a new introduction to methodological foundations Chapter 1.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Session 3: Assessing cost- effectiveness of population level interventions ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research.
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Unit 14: Measures of Public Health Impact.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
PEBB Disease Burden Report PEBB Board of Directors August 21, 2007 Bdattach.10.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
NCHS Data – Strengths and Weaknesses from the NHLBI Perspective Paul Sorlie, Ph.D. Chief, Epidemiology Branch National Heart, Lung, and Blood Institute.
ABCWINRisk and Statistics1 Risk and Statistics Risk Assessment in Clinical Decision Making Ulrich Mansmann Medical Statistics Branch University of Heidelberg.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Cohort Studies.
Skill building: Determining priorities and decision making: Using the best evidence and mindful community process Sharon McDonnell MD MPH.
Session 4: Making a case - ROI and business case for tobacco control ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research Group.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.
Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.
Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)
Evidence and Information for Policy The World Health Survey Health System Metrics Glion, September 2006.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
HSTAT1101: 27. oktober 2004 Odd Aalen
Multiple Choice Questions for discussion
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
IN THE NAME OF GOD Flagship Course on Health Sector Reform and Sustainable Financing; Module 4: : How to construct.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Measures of Association
ANALYTICAL STUDIES Prospective Studies COHORT Prepared by: Dr. Sahar Sabbour Community Medicine Department.
New National Approaches to Immigrant Health Assessment M. DesMeules, J. Gold, B. Vissandjée, J. Payne, A. Kazanjian, D. Manuel Health Canada, University.
Criteria to assess quality of observational studies evaluating the incidence, prevalence, and risk factors of chronic diseases Minnesota EPC Clinical Epidemiology.
SMOKING AND ESTABLISHED CARDIOVASCULAR DISEASE: THE VARIABLE HABITS OF A PRIMARY CARE COHORT Dr Mairead Corrigan 1 PhD BSSc, Dr Margaret E Cupples 1 MD.
Human costs of tobacco-related diseases * Marco Vannotti, France Priez, Claude Jeanrenaud, Jean-Pierre Zellweger Institut de recherches économiques et.
TOWARD AN INVENTORY OF RISK FACTORS ASSOCIATED WITH CHRONIC CONDITIONS Presentation to the Association of Public Health Epidemiologists of Ontario [APHEO]
Tobacco 101. Evolution of Tobacco Evolution of Tobacco.
Cost-Effectiveness of a Diabetes Intervention in Rural India Kushan Shah, B.D.S.; Erin Carlson, DrPH; Sangeeta Shenoy, M.B.B.S.,MPH; Pankaj Shah M.B.B.S.
Measures of Disease Frequency
Integrating a gender perspective into environment statistics Workshop on Integrating a Gender Perspective into National Statistics, Kampala, Uganda 4 -
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Cohort Study Present: Disease Past: Exposure.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Health Statistics and Informatics Non-communicable diseases A global overview.
The Disease Control Priorities Project ( and Chronic Disease Presentation to the Hemispheric Meeting of the Social Protection.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
1 |1 | Workers' Health in the Green Economy and Sustainable Development _____ Dr Ivan D. Ivanov Department of Public Health and Environment World Health.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Date of download: 6/27/2016 From: Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost- Effectiveness Analysis.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
1 Body-Mass Index and Mortality in Korean Men and Women Sun Ha Jee, Ph.D., Jae Woong Sull, Ph.D., Jung yong Park, Ph.D., Sang-Yi Lee, M.D. From the Department.
Vital exhaustion predicts the progression of myocardial infarction-
The University of Sheffield Extrapolation methods:
Benjamin Kearns, The University of Sheffield
Wifi Network Name: RSE Guest Password: RSE
Evidence-based Medicine
Epidemiologic Measures of Association
Background & Objectives
Dr. PJ Devereaux on behalf of POISE Investigators
Measurements of Risk & Association …
Mpundu MKC MSc Epidemiology and Biostatistics, BSc Nursing, RM, RN
No Financial Disclosure or Conflict of Interest
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
Tools to support development of interventions Soili Larkin & Mohammed Vaqar Public Health England West Midlands.
Presentation transcript:

EXPECTED OUTCOMES The study will provide information on the impact of tobacco use on health from epidemiological, social and economic perspectives in relation to the costs incurred in all health sub-sectors, for the diseases and conditions related to the smoking habit. The results will be presented as consequences of smoking on: Mortality, Disability-adjusted life years (DALYs), Quality-adjusted life years (QALYs), Number of events and Total costs. The data produced will serve to hasten the implementation of programs and effective policies for monitoring and reducing tobacco use. They will also serve as input for other researchers in Argentina to objectively assess the impact and the potential health and economic benefits of the measures that promote a reduction of smoking. These results can be essential strategic inputs in convincing the politicians and decision-makers in Argentina to finally ratify the FCTC. Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking in Argentina: Phase II, Extravascular Pathology and Extrapulmonary Tumors Andres Pichon-Riviere MD MSc – Institute for Clinical Effectiveness and Health Policy (IECS – Argentina) OBJECTIVE The aim of this project is to provide relevant data on the disease burden associated with smoking in Argentina, including effects on health and economic impact. BACKGROUND Tobacco control policies have been poor in our region. A contributing factor is the lack of local research on the health and economic consequences of tobacco, and an inappropriate belief of policy makers that tobacco control interventions are less urgent than action on other diseases. Although international evidence about disease burden of tobacco is extensive, it is well known that health economic studies results are not directly transferable from one country to another. There is still a need to more precisely understand the disease burden associated with tobacco measured in terms of clinical consequences (illnesses related to smoking), in years and quality of life as well as economic aspects to inform more efficiently tobacco control policies. The origin of this project is a multi-country collaboration among seven countries in Latin America with the aim of explore each country’s context (decision maker’s attitudes, availability and quality of epidemiological data) in order to select the most suitable methodological framework and elaborate a common health economic evaluation model to be applied in the participant countries as well as in other settings where information is scarce (Research Grants from INCLEN Trust and IC-Health). PRELIMINARY RESULTS Calibration of the model was done by comparing model results with key parameters extracted from Argentina’s vital statistics. Validation was performed with 25 cohorts simulations of 50,000 subjects in each age category (40, 50, 60 and 70 years). In figure 1 and 2 we schematically show the model validation process. Validation showed an excellent external validity (+/-5% of predicted values). Table 1 and Graphic 1 show the main results. Table 1. Model Validation: Predicted vs Expected (Local vital statistics) death rates ParameterNumber of cohort simulations (number of subjects in each cohort) Mortality predicted (per 10,000 person year) MEAN Mean difference between predicted and expected (according to National Vital Statistics) CI95% MI mortality 100 (50,000) %-5.0% a +5.1% Lung Cancer Mortality 100 (50,000)) %-3.1% a +7.2% Non-ischemic cardiovascular disease mortality 100 (50,000) %-5.1% a +1.0% Cerebrovascular disease mortality 100 (50,000) %-5.4% a +1.6% Mortality for all other causes 100 (50,000) %-2.4% a +0.1% Graphic 1. Model Validation: Mean differences between Predicted and Expected death rates. Mean differences are expressed as percentage over expected rates. METHODS (cont.) The main advantages were the possibility of having memory of each subject’s history (as opposed to the “memorylessness” of Markov models); incorporating the possibility of simultaneously experiencing different health states during follow-up (which would render a Markov model nearly unmanageable); and being intrinsically probabilistic. A spreadsheet-based model using Microsoft Excel® was programmed using Visual Basic based Macro functions in order to simulate individual subjects’ experiences. The original model calculates the rate of occurrence of five medical conditions: coronary heart disease (myocardial infarction and unstable angina), non- ischemic cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease and lung cancer. As part of this project we are working to extend this original model in order to include extravascular pathology and extrapulmonary tumors. To populate the model it was necessary to obtain the absolute risk of occurrence of events for the non- smoking subpopulation. Once the baseline risk is derived, the absolute risk for smokers and former smokers could be determined, using the known relative risks. Absolute risks in non-smokers were estimated using local vital statistical data and epidemiological data, and using international figures when data were not available (Formula 1). For the estimation of the probability of a diagnosis of cancer conditions, once the absolute risk of death in the non smokers' population was obtained from the previous formula, this information was utilized to estimate the probability of a diagnosis of lung cancer (Formula 2) METHODS After performing a systematic review of existing health economic models of tobacco we decided to build a microsimulation based model. This model incorporates the natural history, costs and quality of life of the most important tobacco-related diseases. Contact: Andres Pichon-Riviere MD MSc, - Institute for Clinical Efectiveness and Health Policy (IECS – Argentina),